STOCK TITAN

Prevail Therapeutics to Participate in Fireside Chat at Chardan 4th Annual Genetic Medicines Manufacturing Summit

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology firm specializing in AAV-based gene therapies for neurodegenerative diseases, announced that CEO Asa Abeliovich and CTO Yong Dai will engage in a virtual fireside chat at the Chardan 4th Annual Genetic Medicines Manufacturing Summit on May 26, 2020. The discussion will focus on the company's manufacturing and CMC strategy as well as industry trends. Prevail is developing therapies like PR001 for Parkinson’s disease and PR006 for frontotemporal dementia, showcasing their commitment to innovative treatments.

Positive
  • None.
Negative
  • None.

CEO, CTO to Discuss Company’s Manufacturing and CMC Strategy and Overall Industry Trends

NEW YORK, May 21, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail, and Yong Dai, Ph.D., Chief Technology Officer of Prevail will participate in a virtual fireside chat at the Chardan 4th Annual Genetic Medicines Manufacturing Summit on Tuesday, May 26, 2020.

About Prevail Therapeutics
Prevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company is developing PR001 for patients with Parkinson’s disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease; PR006 for patients with frontotemporal dementia with GRN mutations (FTD-GRN); and PR004 for patients with certain synucleinopathies.

Prevail was founded by Dr. Asa Abeliovich in 2017, through a collaborative effort with The Silverstein Foundation for Parkinson’s with GBA and OrbiMed, and is headquartered in New York, NY.

Media Contact:
Mary Carmichael
Ten Bridge Communications
mary@tenbridgecommunications.com
617-413-3543

Investor Contact:
investors@prevailtherapeutics.com

FAQ

What important event is Prevail Therapeutics participating in on May 26, 2020?

Prevail Therapeutics will partake in a virtual fireside chat at the Chardan 4th Annual Genetic Medicines Manufacturing Summit.

Who are the key executives participating in the Prevail Therapeutics event?

CEO Asa Abeliovich and CTO Yong Dai will participate in the event.

What are some of the gene therapies being developed by Prevail Therapeutics?

Prevail is developing PR001 for Parkinson’s disease, PR006 for frontotemporal dementia, and PR004 for certain synucleinopathies.

What is the focus of the discussion at the Chardan Summit involving Prevail Therapeutics?

The discussion will center on the company’s manufacturing and CMC strategy, along with overall industry trends.

Where is Prevail Therapeutics headquartered?

Prevail Therapeutics is headquartered in New York, NY.

PRVL

NASDAQ:PRVL

PRVL Rankings

PRVL Latest News

PRVL Stock Data

29.80M
Biological Product (except Diagnostic) Manufacturing
Manufacturing